10 years ago: Sanofi-Aventis takeover


Aventis has finally accepted a bid from its French rival Sanofi Synthélabo, ending months of wrangling between the two companies and creating the world’s third largest pharmaceutical firm, after Pfizer and GlaxoSmithKline.
Aventis had for some time fought off a €45bn hostile bid from Sanofi, despite the fact that the French government had openly supported the takeover. The government had discouraged a ‘white knight’ bid from Swiss pharmaceutical firm Novartis, openly displaying its enthusiasm for a French national pharmaceutical champion. It also stressed the need for France to guarantee access to vaccines in the event of a terrorist attack.
The new group will be called Sanofi-Aventis, and will be headed by Jean-François Dehecq, Sanofi’s CEO.
Chemistry World (June 2004)

Ed.  Since 2004 Chemistry World has regularly reported on the fortunes of Sanofi-Aventis, which has developed into a global healthcare company, with acquisitions including Zentiva, Medley, Kendricks, Acambis, Symbion and Merial. It is the world’s largest producer of vaccines through its subsidiary Sanofi Pasteur. In 2011, Sanofi-Aventis acquired Genzyme and shareholders approved the change of company name to Sanofi at that year’s combined shareholder meeting.
 


Related Content

Sanofi hostile move for Genzyme

5 October 2010 News Archive

news image

Sanofi-Aventis makes a hostile $18.5 billion takeover bid for US biotech, Genzyme

Business roundup

28 October 2010 Business

news image

Industry news, November 2010

Most Read

Cannabis chemists look for professional recognition

16 October 2014 News and Analysis

news image

The American Chemical Society is being petitioned to form a division to help develop standards in the field

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines

Most Commented

UCLA spent $4.5 million on legal costs in Sangji case

20 October 2014 News and Analysis

news image

University defends spending in case brought against chemistry professor, highlighting $20 million investment in lab safety

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines